Pluristem Shares Commence Trading on Frankfurt Stock Exchange

Wednesday May 9, 8:00 am ET

Pluristem CEO and Chairman, Mr. Zami Aberman commented, "This new listing on the Frankfurt Stock Exchange gives our Company more market exposure and provides our stock higher liquidity in two major equity markets. We also believe it will enhance cooperation with European scientific companies and institutions in the development of our product portfolio."

The Frankfurt listing allows European investors and shareholders to trade Pluristem's shares in their time zone and currency. Located in Frankfurt, Germany, the Frankfurt Stock Exchange is a leading international stock exchange. One of the largest and most efficient exchanges in the world, the Frankfurt Stock Exchange executes over 90 percent of the transactions in the German market and represents a substantial share of the European market. For more information, please visit www.deutsche-boerse.com.

About Pluristem

Pluristem Life Systems, Inc. is a Company dedicated to the commercialization of non-personalized (allogeneic) stem cell therapy products for the treatment of numerous severe degenerative, malignant and autoimmune disorders. The Company's first planned product, PLX-BMT, targets a $2 billion market and is intended to resolve the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood (CB).

Pluristem's products are derived from mesenchymal stem cells (MSCs) obtained from the placenta and expanded in the Company's proprietary PluriX(TM) 3D bioreactor that imitates the natural microstructure of bone marrow and does not require supplemental growth factors, cytokines or other exogenous materials. Pluristem believes the resultant expanded cells, termed PLX cells, are multipotent and able to differentiate into a variety of cell types as well as being immune-privileged to protect the recipient from immunological reactions that often accompanies transplantation. Pluristem believes their future products will participate in the approximate $30 billion therapeutic and regenerative cellular market.

Pluristem has offices and is incorporated in the USA with research and manufacturing facilities in Israel.

www.pluristem.com

Safe Harbor Statement

This press release contains statements, which may constitute "forward-looking statements" regarding our intent, belief or current expectations. Forward-looking statements in this release include that this new listing gives our Company more market exposure and provides our stock higher liquidity in two major equity markets; that it will enhance cooperation with European scientific companies and institutions in the development of our product portfolio. Factors that could prevent our forward looking statements from being achieved include that we may be unable to get regulatory approval for our products; we may be unsuccessful in developing any products; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient to protect essential aspects of our technology; competitors may invent better technology; our products may not work as well as hoped or worse, our products may harm recipients; and we may not be able to raise funds for development or working capital when we require it. As well, our products may never develop into useful products and even if they do, they may not be approved for sale to the public. For further risk factors see the Company's latest 10-KSB filed with the SEC.

For more information visit our website at www.pluristem.com